reviewAlzheimer s & DementiaMar 1, 2025HYBRID OA

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

ALAntoine LeuzyABAriane BollackDPDaniela PellegrinoCECharlotte E. TeunissenRLRenaud La Joie

Lund University · Sahlgrenska University Hospital · +31 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is anticipated to increase with the introduction of new disease-modifying therapies. Although these biomarkers are comparable alternatives in research settings to determine Aβ status, biomarker testing in clinical practice requires careful consideration of the strengths and limitations of each modality, as well as the specific clinical context, to identify which test is best suited for each patient. This article provides a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF…

Citation impact

52
total citations
FWCI
48.15
Percentile
100%
References
324
Citations per year

Authors

19

Topics & keywords

Topics
Keywords
  • Biomarker
  • Medicine
  • Context (archaeology)
  • Positron emission tomography
  • Disease
  • Clinical Practice
  • Intensive care medicine
  • Pathology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding